A Study to Describe the Real-world Effectiveness, Safety and Patterns of Use of Dupilumab in Patients With Chronic Spontaneous Urticaria

NCT07316114 · clinicaltrials.gov ↗

RECRUITING

Status

400

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Spontaneous Urticaria

Interventions

DRUG: Dupilumab

Sponsor

Sanofi

Collaborators

[object Object]